Why randomise in clinical trials?

BMJ (Online)

Volumn 345, Issue 7871, 2012, Pages

  Sedgwick, Philip ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE;

ASCERTAINMENT BIAS; BLOOD ANALYSIS; CLINICAL EXAMINATION; CONFOUNDING VARIABLE; DRUG EFFICACY; EPIDEMIOLOGY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MEDICAL RESEARCH; METHODOLOGY; NOTE; NURSING HOME; OUTCOME ASSESSMENT; PATIENT SELECTION; PLEURA FLUID; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; RESPONSE BIAS; SPUTUM ANALYSIS; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC ERROR; THORAX RADIOGRAPHY; TREATMENT OUTCOME; URINALYSIS;

EID: 84865435882     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e5584     Document Type: Note

References (1)

1. Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010;340:c1004.